Peach Bowl LegACy Fund

We are pleased to announce a Request for Proposal (RFP) for the Peach Bowl LegACy Fund. The purpose of this RFP is to enhance Children’s Healthcare of Atlanta (Children’s) and the Aflac Cancer Center’s ability to open clinical trials for children, adolescents and young adults with pediatric cancers. This includes the development of novel drugs, devices and treatment strategies. The overall goal is to ensure that high-priority novel agents, devices and treatments can be tested in patients in a more rapid manner.

The Letter of Intent (two pages maximum) will be due on Friday, January 19, 2024, by 5 PM EST. All LOIs will be evaluated to determine if projects can move forward with the application process. Notifications will be sent to the PI by Friday, January 27, 2024.

Please email with any questions regarding the Letter of Intent, appropriateness of a specific proposal for this RFP or any other questions regarding the process.

Download RFP

RFP Announcement - 12/01/2023
Letter of Intent Due – 01/19/2024
Application Released - 01/29/2024
Application Due - 3/29/2024
Notification of Winners - June 2024

Recent Recipients

PI: Kelly Goldsmith, MD

Co-PI: Trent Spencer, PhD

Project Title: A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination with Dinutuximab, Temozolomide, and Zoledronate in Children with Refractory or Relapsed Neuroblastoma

PI: Tobey MacDonald, MD

Co-PI: Kavita Dhodapkar, MD

Project Title: AflacST1901 A Phase I Study of WP1066 in Children with Refractory and Progressive or Recurrent Malignant Brain Tumors

PI: Melinda Pauly, MD

Co-PI(s): Thomas Alexander, MD, MPH (UNC), William G. Blum, MD (Emory), Joshua Zeidner, MD (UNC)

Project Title: An Open-Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults with Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia

PI: Kathryn Sutton, MD

Co-PI: W. Thomas Cash, MD, MSc

Project Title: A Maintenance Protocol of Sirolimus in Combination with Metronomic Chemotherapy in Children with High-Risk Solid Tumors

PI: Kirsten Williams, MD

Co-PI: Muna Qayed, MD, MSc

Project Title: CD19/22 CARPOOL: Phase I trial of CD19/22 Chimeric Antigen Receptor Protocol with Objective of Tolerability in relapsed/refractory B-ALL

PI: Bree Eaton, MD

Co-PI(s): Hyunsuk Shim, PhD (Winship) and Claire Mazaewski, MD (Aflac Cancer Center)

Project Title: Spectroscopic MRI for the management of pediatric high-grade glioma patients


PI: Edwin Horwitz, MD, PhD

Co-PI(s): Muna Qayed, MD, MSc

Project Title: Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease after Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies and Myelodysplasia

PI: Robert Craig Castellino, MD

Co-PI(s): Tobey MacDonald, MD

Project Title: First-in-Child Phase I Trial of MinnelideTM in Malignant Pediatric Brain Tumors


PI: Tobey MacDonald, MD

Co-PI(s): Robert Craig Castellino, MD

Project Title: Repurposing Atovaquone for the Treatment of Pediatric Malignant Brain Tumors


PI: Dolly Aguilera, MD

Co-PI(s): Claire Mazewski, MD, Tobey MacDonald, MD, Robert Craig Castellino, MD, Kavita Dhodapkar, MD

Project Title: Phase II, Prospective Trial of Poly-ICLC (Hiltonol) Treatment in Children and Young Adults With Progressive Low-Grace Gliomas


PI: Muna Qayed, MD, MSCR

Co-Pi(s): Nirali Shah, MD, MHSc (National Cancer Institute), Marie Bleakley, MD, PhD (Fred Hutchinson Cancer Research Center),

Project Title: CAR T-cells for Long-TermCure: A Risk-Based Approach to Post CD19 CAR T-cell Consolidation with Hematopoietic Stem Cell Transplantation for Pediatric, Adolescents and Young Adult B-cell Acute Lymphoblastic Leukemia


PI: W. Thomas Cash, MD, MSc

Co-PI(s): Lara Davis, MD (Oregon Health & Science University), J. Andrew Livingstone, MD (UT MD Anderson Cancer Center), Bree Eaton, MD, Megan Durham, MD (Emory University/Children’s)

Project Title: Pilot Study of atezolizumab in combination with stereotactic body radiation therapy (SBRT) and surgery in pediatric and AYA patients with pulmonary recurrence of osteosarcoma

PI: Sunil Raikar, MD

Co-PI(s): Kirsten Williams, MD, H. Trent Spencer, PhD

Project Title: Third-party allogeneic gamma delta T-cells for relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia


PI: W. Thomas Cash, MD, MSc

Co-PI(s): Jason Yustein, MD, PhD

Project Title: A Phase 1b Study of Tegavivint, a TBL1 inhibitor, with Gemcitabine in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma